Cardiology

The supplemental approval for Tyvaso comes on the basis of clinical evidence showing benefit for pulmonary and cardiovascular outcomes in adult patients.

A subgroup analysis from DAPA-HF show the SGLT2 inhibitor provided efficacy regardless of HFrEF patient gender.

An analysis of the YOUNG-MI registry suggests patients aged 50 or younger who suffer a heart attack were at nearly twice the risk of mortality if they had a diagnosis of a systemic inflammatory disease, such as rheumatoid arthritis and lupus, when compared to their counterparts without an inflammatory disease.

Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.

Dr. Gregory Weiss, a critical care cardiologist, offers perspective on a study examining disparities in the diagnosis and treatment of women who experience acute myocardial infarction.

Investigators determined that acid-base disturbances like lactate clearance influenced C diff infection after cardiac surgery.

An analysis of the CHAMP-HF registry indicates KCCQ-OS was more sensitive at tracking changes in disease state among heart failure patients, indicating the importance of including patient-reported outcome measures in heart failure management.

Researchers compare the NYHA class identifier with KCCQ-QS.

The American Heart Association is highlighting the effect of adverse pregnancy outcomes on risk of cardiovascular disease later in life among women. Check out this interview with the chair of the writing committee for more perspective on the statement.

New research suggests use of PET/CT imaging can help identify neurological changes that can signal increased risk of Takotsubo cardiomyopathy, which is commonly referred to as broken heart syndrome.

The FDA announced approval for the Harmony Transcatheter Pulmonary Valve device for treatment of patients with native or surgically-repaired right ventricular outflow tract was awarded to Medtronic Inc.

Data from a single center, retrospective cohort study conducted in Israel suggests undergoing TAVR could lead to improvements in kidney function among patients with aortic stenosis.

The Harmony Transcatheter Pulmonary Valve System is designed to treat adult and pediatric patients with pulmonary valve regurgitation.

The analysis was less statistically powered when comparing sibling discordant.

An expert physician in cardiology and metabolic management walks through a presentation on identifying, addressing, and continually treating for heightened cardiometabolic risk.

An analysis presented at ENDO 2021 suggests less than 5% of patients at high risk for primary aldosteronism undergo screening and most screenings occur after the onset of symptoms.

An analysis of women with polycystic ovary syndrome indicates Black women with the disorder were at a greater risk for heart disease, diabetes, and stroke than their White counterparts.

In this column, Arnold Meshkov, MD, explores the history of the "Thrombus Hypothesis" and his experiences with thrombus in myocardial infarction as a practicing clinician.

As a multi-systemic disorder, Fabry disease can impact the functions of various organs. As a genetic disorder, Fabry can impact the offsprings, parents, and relatives of the patient. Therefore, its effects are far-reaching.

A Michigan State University-led analysis suggests just 3% of patients at high risk for primary aldosteronism underwent screening for the hypertensive disorder.

An analysis comparing propensity-matched data from 4k transgender is providing an updated overview of the risk profile for patients undergoing gender-affirming therapy compared to their cisgender counterparts.

Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.

An analysis of 4k transgender youth and 16k propensity-matched controls is providing insight into the increased risk of conditions adversely impacting the cardiometabolic health of these patients.

The approval is based on positive data from the Phase 3 RAPHSODY trial, which evaluated treatment in older children and adults.

The majority of previous studies have focused on this link in the male population.